Forte Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Forte Biosciences, Inc. on May 29, 2025. The company is incorporated in Delaware and its common stock trades on The NASDAQ Stock Market under the symbol FBRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 6,583,382 shares outstanding as of the April 30, 2025 record date, 5,288,388 shares were represented at the meeting. The following matters were voted upon:
- Election of Class II Directors: All three nominees were elected to serve until the 2028 annual meeting.
- Richard Vincent: 4,083,905 votes for; 15,746 votes withheld.
- Shiv Kapoor: 4,083,436 votes for; 16,215 votes withheld.
- David Gryska: 2,786,414 votes for; 1,313,237 votes withheld.
- Ratification of Independent Auditor: The appointment of KPMG LLP for the fiscal year ending December 31, 2025, was ratified.
- Votes For: 5,285,363
- Votes Against: 2,987
- Abstentions: 38
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director nominee David Gryska (1,313,237) compared to the other nominees.
- Confirm the total number of shares represented at the meeting (5,288,388) against the outstanding shares (6,583,382) to assess participation rates.
- Note the ratification of KPMG LLP as the independent auditor for the 2025 fiscal year.